In last trading session, Cellectar Biosciences Inc (NASDAQ:CLRB) saw 1.18 million shares changing hands with its beta currently measuring 0.92. Company’s recent per share price level of $4.05 trading at $0.18 or 4.65% at ring of the bell on the day assigns it a market valuation of $49.77M. That closing price of CLRB’s stock is at a discount of -9.88% from its 52-week high price of $4.45 and is indicating a premium of 67.9% from its 52-week low price of $1.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.1 million shares which gives us an average trading volume of 1.81 million if we extend that period to 3-months.
Cellectar Biosciences Inc (NASDAQ:CLRB) trade information
Upright in the green during last session for gaining 4.65%, in the last five days CLRB remained trading in the green while hitting it’s week-highest on Friday, 03/22/24 when the stock touched $4.05 price level, adding 1.94% to its value on the day. Cellectar Biosciences Inc’s shares saw a change of 46.21% in year-to-date performance and have moved 16.38% in past 5-day. Cellectar Biosciences Inc (NASDAQ:CLRB) showed a performance of 20.90% in past 30-days. Number of shares sold short was 2.01 million shares which calculate 1.84 days to cover the short interests.
Cellectar Biosciences Inc (CLRB) estimates and forecasts
Statistics highlight that Cellectar Biosciences Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 84.93% of value to its shares in past 6 months, showing an annual growth rate of 25.43% while that of industry is 18.00. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -11.10% in the current quarter and calculating 28.00% increase in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 48.04% during past 5 years.
CLRB Dividends
Cellectar Biosciences Inc is more likely to be releasing its next quarterly report on March 27 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Cellectar Biosciences Inc (NASDAQ:CLRB)’s Major holders
Insiders are in possession of 3.78% of company’s total shares while institution are holding 32.28 percent of that, with stock having share float percentage of 33.55%. Investors also watch the number of corporate investors in a company very closely, which is 32.28% institutions for Cellectar Biosciences Inc that are currently holding shares of the company. Nantahala Capital Management, LLC is the top institutional holder at CLRB for having 2.7 million shares of worth $10.94 million. And as of Dec 30, 2023, it was holding 21.98% of the company’s outstanding shares.
The second largest institutional holder is Rosalind Advisors, Inc., which was holding about 2.01 million shares on Dec 30, 2023. The number of shares represents firm’s hold over 16.32% of outstanding shares, having a total worth of $8.12 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 30, 2023, the former fund manager was holding 0.37 million shares of worth $1.48 million or 2.98% of the total outstanding shares. The later fund manager was in possession of 0.11 million shares on Dec 30, 2023, making its stake of worth around $0.45 million in the company or a holder of 0.90% of company’s stock.
